Biotech Values

[WorstLuck]

ENTA

Enanta has concluded the proof-of-concept study of EDP-494, its cyclophilin inhibitor candidate, in patients with HCV genotypes 1 and 3. Given the high SVR rates in most of the underserved HCV populations demonstrated in phase 3 studies of treatment with G/P in our partnered HCV program, Enanta now believes that G/P has the best and most timely potential for Enanta to participate in the treatment of those HCV patients who have failed on other treatment regimens. Therefore, Enanta has decided to stop further development of EDP-494 and to focus its efforts on its wholly-owned programs in NASH/PBC, RSV and HBV.

http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2234664

Price going higher suggests that value for the other programs were more fully priced in and that the HCV was a negative.